Ascendiant Capital Markets Boosts NRx Pharmaceuticals (NASDAQ:NRXP) Price Target to $44.00

NRx Pharmaceuticals (NASDAQ:NRXP) had its price objective raised by Ascendiant Capital Markets from $43.00 to $44.00 in a research report report published on Thursday, Benzinga reports. The brokerage currently has a buy rating on the stock.

Separately, HC Wainwright raised their price objective on shares of NRx Pharmaceuticals from $2.00 to $19.00 and gave the stock a buy rating in a report on Monday, August 5th.

NRx Pharmaceuticals Price Performance

Shares of NRXP stock opened at $1.72 on Thursday. The stock’s fifty day simple moving average is $2.04 and its 200 day simple moving average is $10.99. NRx Pharmaceuticals has a one year low of $1.59 and a one year high of $7.33. The firm has a market cap of $18.49 million, a price-to-earnings ratio of -0.55 and a beta of 1.25.

NRx Pharmaceuticals (NASDAQ:NRXP) last issued its earnings results on Wednesday, August 14th. The company reported ($0.75) EPS for the quarter, beating the consensus estimate of ($0.81) by $0.06. On average, research analysts anticipate that NRx Pharmaceuticals will post -3.25 earnings per share for the current year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in NRx Pharmaceuticals stock. AdvisorShares Investments LLC acquired a new stake in NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 642,632 shares of the company’s stock, valued at approximately $296,000. AdvisorShares Investments LLC owned approximately 0.75% of NRx Pharmaceuticals at the end of the most recent quarter. 4.27% of the stock is currently owned by institutional investors and hedge funds.

NRx Pharmaceuticals Company Profile

NRx Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned FDA-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.